

TABLE 1 : SVR[†] Rate According to Weight-Based Ribavirin Dosing and Type of Interferon

	Pegylated Interferon[^]	Standard Interferon^{^^}
All patients		
Overall	54% (274/511)	47% (235/505)
Ribavirin dose ≤10.6 mg/kg	50% (160/323)	27% (6/22)
Ribavirin dose >10.6 mg/kg	61% (114/188)	47% (229/483)
Genotype 1		
Overall	42% (145/348)	33% (114/343)
Ribavirin dose ≤10.6 mg/kg	38% (87/226)	20% (3/15)
Ribavirin dose >10.6 mg/kg	48% (58/122)	34% (111/328)
Genotype 2 or 3		
Overall	82% (121/147)	79% (115/146)
Ribavirin dose ≤10.6 mg/kg	79% (70/89)	50% (3/6)
Ribavirin dose >10.6 mg/kg	88% (51/58)	80% (112/140)

†SVR= sustained virologic response [see "Expected Outcome" on page 4]

[^] (PEG-Intron, Schering) 1.5mg/kg/ wk for 48 weeks; ^{^^}3 MIU 3x/wk for 48 weeks

From Manns, et al. Lancet. 2001; 358: 958-965.¹⁶

**TABLE 2:
Monitoring HCV treatment**

<p>Table also applies to HCV/HIV patients</p> <ul style="list-style-type: none"> ➤ Baseline <ul style="list-style-type: none"> ◆ HIV viral load, CD4, CBC, LFTs, Chem panel, HCV load, genotype ◆ Screen for co-morbid disease ◆ Depression screen (consider anti-depressant prophylaxis) ➤ Week 2 <ul style="list-style-type: none"> ◆ CBC ◆ If anemic: erythropoietin or consider adjusting ribavirin dose ➤ 4 week intervals <ul style="list-style-type: none"> ◆ CBC, LFTs, Chem panel ◆ Evaluate mood, adverse effects ➤ 12 week intervals <ul style="list-style-type: none"> ◆ HCV VL, HIV VL, CD4 ◆ Evaluate for drug-drug interactions ◆ Screen for IFN-associated thyroid dysfunction (TSH) ➤ Check HCV VL week 12 and 24 <ul style="list-style-type: none"> ◆ Week 12: HCV RNA > 1 log reduction ◆ Week 24: HCV RNA undetectable ◆ If genotype 1, continue TX for 48 weeks. If non-genotype 1, stop therapy after 24 weeks. <p>VL (viral load); CBC (complete blood count); LFTs (liver function tests); Chem (chemistry panel); TSH (thyroid stimulating hormone).</p>
